Connor, Clark & Lunn Investment Management (CC&L)’s Generation Bio GBIO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,356	Closed	-$67.4K	–	1489
2024 Q4	$67.4K	Sell	6,356 -1,016	-14%	-$18.1K	﹤0.01%	1368
2024 Q3	$182K	Sell	7,372 -284	-4%	-$7.51K	﹤0.01%	1335
2024 Q2	$216K	Sell	7,656 -1,420	-16%	-$46.1K	﹤0.01%	1251
2024 Q1	$369K	Buy	9,076 +6,224	+218%	+$147K	﹤0.01%	1197
2023 Q4	$47.1K	Buy	+2,852	New	+$49.7K	﹤0.01%	1339
2023 Q1	–	Sell	-1,000	Closed	-$39.3K	–	1326
2022 Q4	$39.3K	Buy	+1,000	New	+$52.5K	﹤0.01%	1158

Other funds holding GBIO

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GBIO Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Generation Bio (GBIO) in Q1 2025, closing a stake of 6,356 shares — an estimated $67.4K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GBIO in Q4 2022 and held it in 6 quarters. The position peaked at $369K in Q1 2024. 79 funds tracked by Wall St. Rank hold GBIO as of Q1 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Generation Bio position as of Q1 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 6,356 Generation Bio shares in Q1 2025, an estimated $67.4K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Generation Bio in Q4 2022 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Generation Bio position peaked at $369K in Q1 2024.
79 funds tracked by Wall St. Rank held Generation Bio as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.